Atypical antipsychotic (inhalation)
Loxapine
Brand names: Adasuve
Adult dose
Dose: Adasuve: 9.1 mg single inhalation; may repeat once after 2h
Route: Oral inhalation
Frequency: per episode
Clinical pearls
- Acute mild-moderate agitation in adults with schizophrenia/bipolar mania; supervised setting only with bronchodilator at hand
- SABA must be available before administration
Contraindications
- Asthma
- Acute respiratory disease
- Severe COPD
- Hypersensitivity
Side effects
- Bronchospasm
- Sedation
- Dysgeusia
- EPSE
- QT prolongation
Interactions
- QT-prolonging drugs
- CNS depressants
Monitoring
- BP
- HR
- Respiratory status
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/loxapine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF